- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03627312
Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders
August 9, 2018 updated by: Singapore Prison Service
Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders: A Randomized Controlled Trial
The study aims to examine the effects of providing omega-3 supplements on young offenders' antisocial behaviour.
Participants will be randomized into three groups: (1) Omega-3, (2) Placebo and (3) Treatment as Usual.
Self report and correctional officer ratings of behaviour will be assessed at 0 months (baseline), 3 months (end of supplementation), 6 months and 12 months.
The investigators hypothesize that omega-3 supplementation will reduce antisocial behaviour among the young offenders.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study follows up on two prior omega-3 supplementation Randomized Controlled Trial (RCT) conducted on young offenders - one in the UK (Gesch et al. 2002) and the Netherlands (Zaalberg et al. 2009).
Study Type
Interventional
Enrollment (Actual)
181
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 21 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Admission into young offender's institution
Exclusion Criteria:
- Allergy to fish and fish products
- Serious mental illness and intellectual disability
- Ability to read and write at the level required to complete self report questionnaires
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omega-3
this group receives a fruit juice drink containing omega-3
|
1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
Young Offenders Intervention Programme
|
Placebo Comparator: Placebo
this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
|
Young Offenders Intervention Programme
Fruit juice drink only
|
Other: Treatment as Usual
this group do not receive a fruit juice drink
|
Young Offenders Intervention Programme
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Antisocial Behaviour (Aggression) at 3 months, 6 months and 12 months
Time Frame: 0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Proactive and Reactive Aggression Questionnaire (23 items).
Scale of 0 (Never), 1 (Sometimes) and 2 (Often).
Total range: 0 (min) to 46 (max).
Higher scores indicate higher levels of aggression. 2 subscales: proactive aggression (range: 0 to 22) and reactive aggression (range: 0 to 22).
Total and subscale scores computed by summing up the respective items.
|
0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Change in Antisocial Behaviour (Conduct and Oppositional Defiance) at 3 months, 6 months and 12 months
Time Frame: 0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Conduct and Oppositional Defiant Disorder Questionnaire (20 items).
Scale of 0 (Never), 1 (Sometimes) and 2 (Often).
Total range: 0 (min) to 40 (max).
Higher scores indicate higher levels of Oppositional Defiant Disorder, Conduct Disorder and antisocial behaviour.
2 subscales: Oppositional Defiant Disorder (range: 0 to 16),Conduct Disorder (range: 0 to 24).
Total and subscale scores are computed by summing up the respective items.
|
0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Schizotypal Personality
Time Frame: 0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Schizotypal Personality Questionnaire - Brief.
The questionnaire consist of 22 items, with participants providing responses in a binary (Yes / No) format.
"Yes" is scored as a 1, while "No" is scored a 0, therefore the scale ranges from 0 (min) to 22 (max).
Higher scores represent greater levels of schizotypal personality pattern.
There are three subscales: interpersonal (range: 0 to 8), cognitive perceptual (range: 0 to 8) and disorganized (0 to 6).
Both total and subscale scores are computed by summing up the respective items.
|
0 Months (baseline), 3 Months, 6 Months, 12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Adrian Raine, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2011
Primary Completion (Actual)
July 31, 2013
Study Completion (Actual)
July 31, 2013
Study Registration Dates
First Submitted
July 31, 2018
First Submitted That Met QC Criteria
August 9, 2018
First Posted (Actual)
August 13, 2018
Study Record Updates
Last Update Posted (Actual)
August 13, 2018
Last Update Submitted That Met QC Criteria
August 9, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SingaporePS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Requests for data will be reviewed by the Singapore Prison Service.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antisocial Behavior
-
University of MichiganCompletedViolence | Child or Adolescent Antisocial BehaviorUnited States
-
Dr. Annis FungUniversity of Pennsylvania; The University of Hong Kong; Brooklyn College of...CompletedAggression | Antisocial Behavior | Antisocial PersonalityChina
-
Oregon Social Learning CenterUniversity of Massachusetts, Worcester; Chestnut Health Systems; Connecticut... and other collaboratorsActive, not recruitingAntisocial BehaviorUnited States
-
University of Massachusetts, WorcesterNational Institute of Mental Health (NIMH); Oregon Social Learning Center; Connecticut... and other collaboratorsCompleted
-
University of PennsylvaniaCompletedAggression | Antisocial BehaviorUnited States
-
The University of QueenslandRestorative Outcomes Australia; Department of Education, Queensland; Queensland... and other collaboratorsUnknownAntisocial Behavior | School Attendance | Welfare DependenceAustralia
-
Nanyang Technological UniversityActive, not recruiting
-
Wetenschappelijk Onderzoek en DatacentrumLeiden University; Utrecht UniversityRecruitingDelinquency | Criminal Recidivism | Antisocial BehaviorNetherlands
-
University of PennsylvaniaCompletedAggression | Antisocial BehaviorUnited States
-
Olivia ChoyRWTH Aachen UniversityCompletedAggression | Risk-Taking | Antisocial BehaviorGermany
Clinical Trials on Omega-3
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Pennington Biomedical Research CenterCompleted
-
AstraZenecaCompletedDiabetes Mellitus, Type 2 | Exocrine Pancreatic InsufficiencySweden, Poland, Latvia, Denmark, Hungary, Slovakia
-
Appalachian State UniversityCompleted
-
Seoul National University HospitalUnknown
-
Université de SherbrookeNot yet recruiting
-
Collegium Medicum w BydgoszczyUnknownChronic Kidney Disease | Cardiovascular ComplicationsPoland
-
Haukeland University HospitalUniversity of Oslo; University of BergenCompletedCardiovascular Disease
-
Université de SherbrookeSamuel Fortin, SFC pharma and associate professor UQARCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted